{"transactions":[{"id":856485,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-04","kind":"grant","planned":true,"acquired":true,"shares":6519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month\nperiod, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":6519,"derivative":{"exercise_price":434.8,"expiration_date":"2036-03-04","underlying":"Common Stock","underlying_shares":6519},"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856484,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":40,"price":437.65,"value":17506.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."}],"balance_after":12490,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856483,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":80,"price":436.69,"value":34935.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive."}],"balance_after":12530,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856482,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":80,"price":435.315,"value":34825.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive."}],"balance_after":12610,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856481,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":160,"price":434.2,"value":69472.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive."}],"balance_after":12690,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856480,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":116,"price":432.5559,"value":50176.4844,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive."}],"balance_after":12850,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856479,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":120,"price":430.9033,"value":51708.396,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive."}],"balance_after":12966,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856478,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":40,"price":429.58,"value":17183.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."}],"balance_after":13086,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856477,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":160,"price":428.995,"value":68639.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive."}],"balance_after":13126,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856476,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":80,"price":427.845,"value":34227.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive."}],"balance_after":13286,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856475,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":420,"price":426.8638,"value":179282.796,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below."}],"balance_after":13366,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856474,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":40,"price":425.08,"value":17003.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."}],"balance_after":13786,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856473,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":646,"price":431.94,"value":279033.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."}],"balance_after":13826,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":856472,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-07T00:18:32.000Z","date":"2026-03-04","kind":"grant","planned":true,"acquired":true,"shares":5215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues\nin service with the Issuer on each such date."}],"balance_after":14472,"source":{"system":"sec-edgar","filing":"0001628280-26-015775","document":"wk-form4_1772842708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015775/wk-form4_1772842708.xml","form_type":"4"}},{"id":874960,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2026-03-02T22:32:35.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":1183,"price":427.21,"value":505389.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."}],"balance_after":9257,"source":{"system":"sec-edgar","filing":"0001628280-26-013394","document":"wk-form4_1772490753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026013394/wk-form4_1772490753.xml","form_type":"4"}},{"id":945738,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T16:44:42.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026."}],"balance_after":40000,"derivative":{"exercise_price":8.17,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001574591-26-000002","document":"form4-01062026_090138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000157459126000002/form4-01062026_090138.xml","form_type":"4"}},{"id":982099,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"exercise","planned":true,"acquired":false,"shares":4173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"All shares issued pursuant to the exercise of the options reported herein represent 4,173 shares underlying an overall option award of 13,353 shares. All exercised options had vested. As to the overall option for 13,353 shares, 25% of the shares vested on March 1, 2025, and, thereafter, 6.25% of the shares vested or will vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":9180,"derivative":{"exercise_price":251.63,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":4173},"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982098,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":80,"price":596.185,"value":47694.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $596.18 to $596.19, inclusive."}],"balance_after":10440,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982097,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":74,"price":595.2047,"value":44045.1478,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $595.18 to $595.41, inclusive."}],"balance_after":10520,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982096,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":160,"price":590.3725,"value":94459.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.15 to $590.58, inclusive."}],"balance_after":10594,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982095,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":160,"price":589.6479,"value":94343.664,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.13 to $589.96, inclusive."}],"balance_after":10754,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982094,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":240,"price":587.8495,"value":141083.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.58 to $588.07, inclusive."}],"balance_after":10914,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982093,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":240,"price":585.4383,"value":140505.192,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.08 to $585.99, inclusive."}],"balance_after":11154,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982092,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":480,"price":579.8525,"value":278329.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.59 to $580.46, inclusive."}],"balance_after":11394,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982091,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":258,"price":578.831,"value":149338.398,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $578.37 to $579.20, inclusive."}],"balance_after":11874,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982090,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":320,"price":577.8144,"value":184900.608,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.36 to $578.31, inclusive."}],"balance_after":12132,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982089,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":240,"price":576.1517,"value":138276.408,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.69 to $576.46, inclusive."}],"balance_after":12452,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982088,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":120,"price":574.9524,"value":68994.288,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.67 to $575.24, inclusive."}],"balance_after":12692,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982087,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":717,"price":574.0011,"value":411558.7887,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.59 to $574.44, inclusive."}],"balance_after":12812,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982086,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":354,"price":573.0151,"value":202847.3454,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.48 to $573.38, inclusive."}],"balance_after":13529,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982085,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":410,"price":571.9892,"value":234515.572,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.45 to $572.34, inclusive."}],"balance_after":13883,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982084,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":320,"price":570.386,"value":182523.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.17 to $570.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below."}],"balance_after":14293,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":982083,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2025-12-03T22:59:33.000Z","date":"2025-12-02","kind":"exercise","planned":true,"acquired":true,"shares":4173,"price":251.63,"value":1050051.99,"ownership":{"direct":true},"balance_after":14613,"source":{"system":"sec-edgar","filing":"0001628280-25-055164","document":"wk-form4_1764802770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055164/wk-form4_1764802770.xml","form_type":"4"}},{"id":1111052,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-13T16:15:27.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":38000,"derivative":{"exercise_price":1.04,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001562180-25-004797","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000156218025004797/primarydocument.xml","form_type":"4"}},{"id":1210313,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-03-12T20:32:09.000Z","date":"2025-03-10","kind":"sale","planned":true,"acquired":false,"shares":258,"price":323.04,"value":83344.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2024."}],"balance_after":10440,"source":{"system":"sec-edgar","filing":"0001628280-25-012369","document":"wk-form4_1741811523.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025012369/wk-form4_1741811523.xml","form_type":"4"}},{"id":1217921,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-07T22:43:59.000Z","date":"2025-03-05","kind":"grant","planned":false,"acquired":true,"shares":6374,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":6374,"derivative":{"exercise_price":347.28,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":6374},"source":{"system":"sec-edgar","filing":"0001628280-25-011407","document":"wk-form4_1741387433.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011407/wk-form4_1741387433.xml","form_type":"4"}},{"id":1217920,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-03-07T22:43:59.000Z","date":"2025-03-05","kind":"grant","planned":false,"acquired":true,"shares":3784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":10698,"source":{"system":"sec-edgar","filing":"0001628280-25-011407","document":"wk-form4_1741387433.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011407/wk-form4_1741387433.xml","form_type":"4"}},{"id":1223441,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-03-05T21:31:51.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":774,"price":323.5357,"value":250416.6318,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.38 to $323.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":6914,"source":{"system":"sec-edgar","filing":"0001628280-25-010508","document":"wk-form4_1741210303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025010508/wk-form4_1741210303.xml","form_type":"4"}},{"id":1223440,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and CFO"}}],"security":"Common Stock","published_at":"2025-03-05T21:31:51.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":1187,"price":325.89,"value":386831.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."}],"balance_after":7688,"source":{"system":"sec-edgar","filing":"0001628280-25-010508","document":"wk-form4_1741210303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025010508/wk-form4_1741210303.xml","form_type":"4"}},{"id":1309739,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T16:43:37.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025."}],"balance_after":35000,"derivative":{"exercise_price":8.26,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-000782","document":"form4-01062025_090133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000141588925000782/form4-01062025_090133.xml","form_type":"4"}},{"id":1474694,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-06-18T16:13:20.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":23500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":23500,"derivative":{"exercise_price":3.9,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":23500},"source":{"system":"sec-edgar","filing":"0001562180-24-005161","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000156218024005161/primarydocument.xml","form_type":"4"}},{"id":1478532,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T16:22:42.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":25600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":25600,"derivative":{"exercise_price":7.9,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":25600},"source":{"system":"sec-edgar","filing":"0001415889-24-016906","document":"form4-06142024_080637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000141588924016906/form4-06142024_080637.xml","form_type":"4"}},{"id":1847538,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-21T16:13:35.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":23500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":23500,"derivative":{"exercise_price":5.56,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":23500},"source":{"system":"sec-edgar","filing":"0001209191-23-038773","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919123038773/doc4.xml","form_type":"4"}},{"id":1853883,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T16:52:57.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":20500,"derivative":{"exercise_price":6.33,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-23-037393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919123037393/doc4.xml","form_type":"4"}},{"id":1896393,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-05-11T20:51:59.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":85226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":85226,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":85226},"source":{"system":"sec-edgar","filing":"0001209191-23-028864","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919123028864/doc4.xml","form_type":"4"}},{"id":1896392,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-05-11T20:51:59.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":85226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Class A Common Stock","underlying_shares":85226},"source":{"system":"sec-edgar","filing":"0001209191-23-028864","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919123028864/doc4.xml","form_type":"4"}},{"id":1896391,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-05-11T20:51:59.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":673621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":673621,"derivative":{"exercise_price":5.8766,"expiration_date":"2032-11-20","underlying":"Common Stock","underlying_shares":673621},"source":{"system":"sec-edgar","filing":"0001209191-23-028864","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919123028864/doc4.xml","form_type":"4"}},{"id":1896390,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-05-11T20:51:59.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":673621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":0,"derivative":{"exercise_price":5.8766,"expiration_date":"2032-11-20","underlying":"Class A Common Stock","underlying_shares":673621},"source":{"system":"sec-edgar","filing":"0001209191-23-028864","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919123028864/doc4.xml","form_type":"4"}},{"id":1896389,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-05-11T20:51:59.000Z","date":"2023-05-09","kind":"purchase","planned":false,"acquired":true,"shares":875,"price":18,"value":15750.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by another one of the Reporting Person's children."}],"balance_after":875,"source":{"system":"sec-edgar","filing":"0001209191-23-028864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919123028864/doc4.xml","form_type":"4"}},{"id":1896388,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-05-11T20:51:59.000Z","date":"2023-05-09","kind":"purchase","planned":false,"acquired":true,"shares":875,"price":18,"value":15750.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by one of the Reporting Person's children."}],"balance_after":875,"source":{"system":"sec-edgar","filing":"0001209191-23-028864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919123028864/doc4.xml","form_type":"4"}},{"id":1896387,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-05-11T20:51:59.000Z","date":"2023-05-09","kind":"purchase","planned":false,"acquired":true,"shares":5556,"price":18,"value":100008.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the \"IPO\")."}],"balance_after":5556,"source":{"system":"sec-edgar","filing":"0001209191-23-028864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919123028864/doc4.xml","form_type":"4"}},{"id":1904050,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-05-04T19:59:45.000Z","date":"2023-05-04","kind":"grant","planned":false,"acquired":true,"shares":85226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."}],"balance_after":85226,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Class A Common Stock","underlying_shares":85226},"source":{"system":"sec-edgar","filing":"0001209191-23-027513","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919123027513/doc4.xml","form_type":"4"}},{"id":2136196,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2022-10-17T22:49:56.000Z","date":"2022-10-14","kind":"sale","acquired":false,"shares":1629,"price":40.16,"value":65420.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":66695,"source":{"system":"sec-edgar","filing":"0001209191-22-053884","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919122053884/doc4.xml","form_type":"4"}},{"id":2136899,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2022-10-14T16:58:31.000Z","date":"2022-10-12","kind":"sale","acquired":false,"shares":3484,"price":38.22,"value":133158.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":68324,"source":{"system":"sec-edgar","filing":"0001209191-22-053647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919122053647/doc4.xml","form_type":"4"}},{"id":2155314,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2022-09-20T01:39:31.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":71808,"source":{"system":"sec-edgar","filing":"0001209191-22-050670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919122050670/doc4.xml","form_type":"4"}},{"id":2223778,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-06-22T16:13:58.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":34300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":34300,"derivative":{"exercise_price":4.74,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":34300},"source":{"system":"sec-edgar","filing":"0001562180-22-005297","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000156218022005297/primarydocument.xml","form_type":"4"}},{"id":2226724,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T20:19:08.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":53700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B)  one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022."}],"balance_after":53700,"derivative":{"exercise_price":3.75,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":53700},"source":{"system":"sec-edgar","filing":"0001209191-22-038197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919122038197/doc4.xml","form_type":"4"}},{"id":2353069,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T23:12:02.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":24900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":24900,"derivative":{"exercise_price":67.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":24900},"source":{"system":"sec-edgar","filing":"0001209191-22-015833","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919122015833/doc4.xml","form_type":"4"}},{"id":2353068,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2022-03-03T23:12:02.000Z","date":"2022-03-03","kind":"sale","acquired":false,"shares":420,"price":64.55,"value":27111.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales on March 3, 2022 reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":51808,"source":{"system":"sec-edgar","filing":"0001209191-22-015833","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919122015833/doc4.xml","form_type":"4"}},{"id":2353067,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2022-03-03T23:12:02.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."}],"balance_after":52228,"source":{"system":"sec-edgar","filing":"0001209191-22-015833","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919122015833/doc4.xml","form_type":"4"}},{"id":2353066,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2022-03-03T23:12:02.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":534,"price":66.62,"value":35575.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."}],"balance_after":38228,"source":{"system":"sec-edgar","filing":"0001209191-22-015833","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919122015833/doc4.xml","form_type":"4"}},{"id":2542237,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2021-10-14T22:33:08.000Z","date":"2021-10-14","kind":"sale","acquired":false,"shares":3261,"price":81.16,"value":264662.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this row on this Form 4 was effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.55 to $81.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":38762,"source":{"system":"sec-edgar","filing":"0001209191-21-060504","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121060504/doc4.xml","form_type":"4"}},{"id":2542236,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2021-10-14T22:33:08.000Z","date":"2021-10-12","kind":"sale","acquired":false,"shares":3477,"price":82.79,"value":287860.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."}],"balance_after":42023,"source":{"system":"sec-edgar","filing":"0001209191-21-060504","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121060504/doc4.xml","form_type":"4"}},{"id":2658366,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-06-22T17:40:01.000Z","date":"2021-06-18","kind":"grant","acquired":true,"shares":23344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":23344,"derivative":{"exercise_price":31.02,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":23344},"source":{"system":"sec-edgar","filing":"0001209191-21-042471","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919121042471/doc4.xml","form_type":"4"}},{"id":2662940,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T19:42:27.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":16625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 16, 2022 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":16625,"derivative":{"exercise_price":19.03,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":16625},"source":{"system":"sec-edgar","filing":"0001209191-21-041738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919121041738/doc4.xml","form_type":"4"}},{"id":2680578,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T16:13:53.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date."}],"balance_after":10000,"derivative":{"exercise_price":5.21,"exercise_date":"2022-06-02","expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001328143-21-000056","document":"wf-form4_162283761559047.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000056/wf-form4_162283761559047.xml","form_type":"4"}},{"id":2680577,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T16:13:53.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001328143-21-000056","document":"wf-form4_162283761559047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000056/wf-form4_162283761559047.xml","form_type":"4"}},{"id":2811733,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-04T01:38:52.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":11000,"derivative":{"exercise_price":142.47,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-21-017541","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121017541/doc4.xml","form_type":"4"}},{"id":2811732,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2021-03-04T01:38:52.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001209191-21-017541","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919121017541/doc4.xml","form_type":"4"}},{"id":3007968,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-13T21:52:53.000Z","date":"2020-10-12","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":40000,"derivative":{"exercise_price":95.5,"expiration_date":"2030-10-12","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-20-054709","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919120054709/doc4.xml","form_type":"4"}},{"id":3007967,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Executive Vice President"}}],"security":"Common Stock","published_at":"2020-10-13T21:52:53.000Z","date":"2020-10-12","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001209191-20-054709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1515673/000120919120054709/doc4.xml","form_type":"4"}},{"id":3020568,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-29T20:09:27.000Z","date":"2020-09-29","kind":"purchase","acquired":true,"shares":10000,"price":19,"value":190000.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-20-052403","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919120052403/doc4.xml","form_type":"4"}},{"id":3021526,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-09-28T19:35:29.000Z","date":"2020-09-24","kind":"grant","acquired":true,"shares":3458,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/36 of the total shares monthly beginning on September 24, 2020 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":3458,"derivative":{"exercise_price":19,"expiration_date":"2030-09-23","underlying":"Common Stock","underlying_shares":3458},"source":{"system":"sec-edgar","filing":"0001209191-20-052266","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919120052266/doc4.xml","form_type":"4"}},{"id":3091326,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Restricted Stock Units","published_at":"2020-07-02T16:25:20.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":32291,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"At the Effective Time, each restricted stock unit (\"Issuer RSU\") was converted into a restricted stock unit, subject to substantially the same terms\nand conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying\n(i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"At the Effective Time, each restricted stock unit (\"Issuer RSU\") was converted into a restricted stock unit, subject to substantially the same terms\nand conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying\n(i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"At the Effective Time, each restricted stock unit (\"Issuer RSU\") was converted into a restricted stock unit, subject to substantially the same terms\nand conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying\n(i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":32291},"source":{"system":"sec-edgar","filing":"0001209191-20-040307","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040307/doc4.xml","form_type":"4"}},{"id":3091325,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T16:25:20.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":371545,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"In connection with the Merger, these options were accelerated and canceled without payment."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"In connection with the Merger, these options were accelerated and canceled without payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"In connection with the Merger, these options were accelerated and canceled without payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"In connection with the Merger, these options were accelerated and canceled without payment."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":371545},"source":{"system":"sec-edgar","filing":"0001209191-20-040307","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040307/doc4.xml","form_type":"4"}},{"id":3091324,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T16:25:20.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law."}],"balance_after":0,"derivative":{"exercise_price":12.79,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001209191-20-040307","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040307/doc4.xml","form_type":"4"}},{"id":3091323,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T16:25:20.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":65000,"price":5.21,"value":338650.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law."}],"balance_after":0,"derivative":{"exercise_price":12.79,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-20-040307","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040307/doc4.xml","form_type":"4"}},{"id":3091322,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Performance Stock Units","published_at":"2020-07-02T16:25:20.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":24375,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24375},"source":{"system":"sec-edgar","filing":"0001209191-20-040307","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040307/doc4.xml","form_type":"4"}},{"id":3091321,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Performance Stock Units","published_at":"2020-07-02T16:25:20.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":48750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each performance restricted stock unit ( \"Issuer PSU\") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the \"Exchange Ratio\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each performance restricted stock unit ( \"Issuer PSU\") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the \"Exchange Ratio\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each performance restricted stock unit ( \"Issuer PSU\") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the \"Exchange Ratio\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":48750},"source":{"system":"sec-edgar","filing":"0001209191-20-040307","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040307/doc4.xml","form_type":"4"}},{"id":3091320,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2020-07-02T16:25:20.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":10,"price":18,"value":180.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the \"Issuer\"), Alexion Pharmaceuticals, Inc. (\"Alexion\") and Odyssey Merger Sub Inc. (\"Merger Sub\") (the \"Merger Agreement\"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-040307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040307/doc4.xml","form_type":"4"}},{"id":3091319,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2020-07-02T16:25:20.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":10,"price":8.36,"value":83.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The acquisition of 10 shares by the Reporting Person on June 18, 2020 pursuant to the Issuer's Employee Stock Purchase Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The acquisition of 10 shares by the Reporting Person on June 18, 2020 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":10,"source":{"system":"sec-edgar","filing":"0001209191-20-040307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040307/doc4.xml","form_type":"4"}},{"id":3091318,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CFO"}}],"security":"Common Stock","published_at":"2020-07-02T16:25:20.000Z","date":"2020-07-02","kind":"disposition_to_issuer","acquired":false,"shares":39563,"price":18,"value":712134.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the \"Issuer\"), Alexion Pharmaceuticals, Inc. (\"Alexion\") and Odyssey Merger Sub Inc. (\"Merger Sub\") (the \"Merger Agreement\"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-040307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120040307/doc4.xml","form_type":"4"}},{"id":3120012,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-05T18:09:20.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 3, 2020, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date."}],"balance_after":10000,"derivative":{"exercise_price":2.7,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-034777","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919120034777/doc4.xml","form_type":"4"}},{"id":3120011,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-05T18:09:20.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the date 1 year from June 3, 2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-20-034777","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919120034777/doc4.xml","form_type":"4"}},{"id":3168891,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-04-27T16:41:41.000Z","date":"2020-04-23","kind":"grant","acquired":true,"shares":33250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth (1/36) of the shares subject to the option shall vest May 23, 2020, and an additional thirty-sixth (1/36) of the shares subject to the option shall vest each month thereafter."}],"balance_after":33250,"derivative":{"exercise_price":16,"expiration_date":"2030-04-22","underlying":"Common Stock","underlying_shares":33250},"source":{"system":"sec-edgar","filing":"0001209191-20-025807","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574591/000120919120025807/doc4.xml","form_type":"4"}},{"id":3231646,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2020-03-03T18:51:47.000Z","date":"2020-03-02","kind":"tax_withholding","acquired":false,"shares":4543,"price":9.68,"value":43976.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,239 shares acquired under the Issuer's employee stock purchase plan on February 28, 2020."}],"balance_after":78229,"source":{"system":"sec-edgar","filing":"0001209191-20-015647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120015647/doc4.xml","form_type":"4"}},{"id":3246015,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Performance Stock Unit","published_at":"2020-02-26T20:10:07.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":73125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit (PSU) represents a contingent right to receive one (1) share of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"One-third of the PSUs will be earned one or after the one (1) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 50% per share from the grant date closing price of Issuer's Common Stock on the Nasdaq Global Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"One-third of the PSUs will be earned on or after the two (2) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 100% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"One-third of the PSUs will be earned on the three (3) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 150% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (2) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third of the PSUs will be earned one or after the one (1) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 50% per share from the grant date closing price of Issuer's Common Stock on the Nasdaq Global Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the PSUs will be earned on or after the two (2) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 100% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-third of the PSUs will be earned on the three (3) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 150% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (2) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06."}],"balance_after":73125,"derivative":{"expiration_date":"2023-02-24","underlying":"Common Stock","underlying_shares":73125},"source":{"system":"sec-edgar","filing":"0001209191-20-013253","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120013253/doc4.xml","form_type":"4"}},{"id":3291150,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-04T18:51:46.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 31, 2020, subject to the Reporting Person's Continuous Service as of each such date."}],"balance_after":65000,"derivative":{"exercise_price":12.79,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-20-006640","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120006640/doc4.xml","form_type":"4"}},{"id":3291149,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2020-02-04T18:51:46.000Z","date":"2020-02-03","kind":"tax_withholding","acquired":false,"shares":3435,"price":12.89,"value":44277.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":81533,"source":{"system":"sec-edgar","filing":"0001209191-20-006640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120006640/doc4.xml","form_type":"4"}},{"id":3291148,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2020-02-04T18:51:46.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSUs\") in consideration of services rendered. The RSUs vest in three equal annual installments subject to Reporting Person's Continuous Service under the Issuer's plan documents as of each vest date."}],"balance_after":84968,"source":{"system":"sec-edgar","filing":"0001209191-20-006640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120006640/doc4.xml","form_type":"4"}},{"id":3311472,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2020-01-14T19:45:33.000Z","date":"2020-01-14","kind":"tax_withholding","acquired":false,"shares":1277,"price":13.8,"value":17622.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":68718,"source":{"system":"sec-edgar","filing":"0001209191-20-003374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120003374/doc4.xml","form_type":"4"}},{"id":3311471,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2020-01-14T19:45:33.000Z","date":"2020-01-12","kind":"grant","acquired":true,"shares":2125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Performance Stock Unit (\"PSU\") granted March 29, 2018 represented a contingent right to receive one share of Issuer's Common Stock. 2,125 PSUs time-vested on January 12, 2020 on the one year anniversary of the certification by the Issuer's Compensation Committee of the FDA's December 31, 2018 approval of Andexxa Gen 2 in the United States."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 425 shares of common stock acquired under the PTLA stock purchase plan on August 30, 2019 in an exempt transaction."}],"balance_after":69995,"source":{"system":"sec-edgar","filing":"0001209191-20-003374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919120003374/doc4.xml","form_type":"4"}},{"id":3498541,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-06T16:15:07.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 5, 2019, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date."}],"balance_after":10000,"derivative":{"exercise_price":4.8,"expiration_date":"2029-06-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-035054","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919119035054/doc4.xml","form_type":"4"}},{"id":3516686,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Performance Stock Unit","published_at":"2019-05-21T20:28:10.000Z","date":"2019-05-19","kind":"exercise","acquired":false,"shares":5859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Performance Stock Unit (\"PSU\") granted January 30, 2017 represented a contingent right to receive one (1) share of the Issuer's Common Stock. 5,859 became vested on the upon the first anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Performance Stock Unit (\"PSU\") granted January 30, 2017 represented a contingent right to receive one (1) share of the Issuer's Common Stock. 5,859 became vested on the upon the first anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018."}],"balance_after":0,"derivative":{"expiration_date":"2027-01-30","underlying":"Common Stock","underlying_shares":5859},"source":{"system":"sec-edgar","filing":"0001209191-19-031877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119031877/doc4.xml","form_type":"4"}},{"id":3516685,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2019-05-21T20:28:10.000Z","date":"2019-05-20","kind":"tax_withholding","acquired":false,"shares":3022,"price":28.69,"value":86701.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":69570,"source":{"system":"sec-edgar","filing":"0001209191-19-031877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119031877/doc4.xml","form_type":"4"}},{"id":3516684,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2019-05-21T20:28:10.000Z","date":"2019-05-19","kind":"grant","acquired":true,"shares":5859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Performance Stock Unit (\"PSU\") granted January 30, 2017 represented a contingent right to receive one (1) share of the Issuer's Common Stock. 5,859 became vested on the upon the first anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018."}],"balance_after":72592,"source":{"system":"sec-edgar","filing":"0001209191-19-031877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119031877/doc4.xml","form_type":"4"}},{"id":3560206,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2019-04-08T19:03:37.000Z","date":"2019-04-04","kind":"sale","acquired":false,"shares":40486,"price":37.3913,"value":1513824.1718,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.1000 to $37.7400, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) to this Form 4."}],"balance_after":66733,"source":{"system":"sec-edgar","filing":"0001209191-19-024043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119024043/doc4.xml","form_type":"4"}},{"id":3611462,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2019-03-05T18:26:44.000Z","date":"2019-03-04","kind":"tax_withholding","acquired":false,"shares":9667,"price":33.41,"value":322974.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":107219,"source":{"system":"sec-edgar","filing":"0001209191-19-016965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119016965/doc4.xml","form_type":"4"}},{"id":3677188,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-04T17:47:01.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 31, 2019, subject to the Reporting Person's Continuous Service as of each such date."}],"balance_after":75000,"derivative":{"exercise_price":27.1,"expiration_date":"2029-01-30","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-19-006896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119006896/doc4.xml","form_type":"4"}},{"id":3677187,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":62346,"kind":"person","name":"Dier Mardi","position":1,"cik":"0001574591","reported_name":"Dier Mardi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CFO & CBO"}}],"security":"Common Stock","published_at":"2019-02-04T17:47:01.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSUs\") in consideration of services rendered. The RSUs vest in three equal annual installments on January 31, 2020, January 31, 2021 and January 31, 2022, subject to Reporting Person's Continuous Service under the Issuer's plan documents as of each such date."}],"balance_after":116682,"source":{"system":"sec-edgar","filing":"0001209191-19-006896","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119006896/doc4.xml","form_type":"4"}}],"next_cursor":"2019-02-04T17:47:01.000000Z,3677187"}